Exchange Traded Concepts LLC Decreases Stake in Humana Inc. $HUM

Exchange Traded Concepts LLC reduced its position in shares of Humana Inc. (NYSE:HUM) by 52.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,389 shares of the insurance provider’s stock after selling 1,526 shares during the period. Exchange Traded Concepts LLC’s holdings in Humana were worth $552,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Humana by 4.1% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 250,330 shares of the insurance provider’s stock worth $66,207,000 after acquiring an additional 9,960 shares in the last quarter. Sustainable Insight Capital Management LLC boosted its holdings in Humana by 23.7% in the fourth quarter. Sustainable Insight Capital Management LLC now owns 24,757 shares of the insurance provider’s stock valued at $6,341,000 after purchasing an additional 4,740 shares in the last quarter. Ninety One UK Ltd increased its stake in Humana by 57.2% in the fourth quarter. Ninety One UK Ltd now owns 112,501 shares of the insurance provider’s stock valued at $28,815,000 after purchasing an additional 40,958 shares during the last quarter. Swedbank AB raised its holdings in Humana by 6.2% during the fourth quarter. Swedbank AB now owns 111,803 shares of the insurance provider’s stock worth $28,636,000 after purchasing an additional 6,534 shares in the last quarter. Finally, North Dakota State Investment Board acquired a new stake in Humana during the fourth quarter worth approximately $1,517,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Key Headlines Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Higher earnings outlook: Zacks Research raised its Q1 2027 EPS estimate to $9.04 from $8.70, suggesting improved expectations for Humana’s near-term profitability. The firm nonetheless maintained a Hold rating. Humana earnings estimate article
• Positive Sentiment: Medicaid and underserved-member expansion: Humana is partnering with Cityblock Health to support low-income and dual-eligible Medicare Advantage members. The move could strengthen care coordination and support growth in Medicaid and Medicare-related services. Humana Cityblock partnership article
• Positive Sentiment: Caregiver-retention initiative: A HealthStream agreement will fund 1,000 caregiver scholarships and provide recruitment and retention tools in Indiana, potentially supporting staffing at Humana’s CenterWell operations. Humana HealthStream deal article
• Positive Sentiment: Brokerage price-target support: JPMorgan raised its price target for HUM to $393, indicating modest upside relative to the referenced trading level. JPMorgan Humana price target article
• Neutral Sentiment: Leadership change: Humana appointed James Holland as president of its Medicaid business, underscoring the company’s focus on Medicaid but creating an execution milestone for investors. Humana Medicaid leadership article
• Neutral Sentiment: Legal proceeding: Humana agreed not to reference Teva’s Israeli identity during an upcoming U.S. drug-price-fixing trial. The agreement is procedural and does not indicate a new financial liability for Humana. Humana Teva trial article
• Negative Sentiment: Medicare Advantage membership reduction: Humana reportedly plans to drop approximately 600,000 Medicare Advantage members in 2027. Although the move may improve plan economics, investors may view the lost membership and related revenue as a near-term headwind. Humana Medicare Advantage membership article
• Negative Sentiment: More cautious rating: Zacks Research downgraded Humana from Strong Buy to Hold, limiting the positive impact from the firm’s higher EPS forecast. Zacks Humana rating

Humana Stock Down 1.1%

HUM stock opened at $384.50 on Friday. The company has a market cap of $46.17 billion, a price-to-earnings ratio of 36.38, a price-to-earnings-growth ratio of 2.22 and a beta of 0.72. The company has a fifty day moving average price of $381.25 and a 200 day moving average price of $274.88. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $428.88.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, beating analysts’ consensus estimates of $7.27 by $0.34. Humana had a net margin of 0.88% and a return on equity of 11.20%. The company had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. During the same period in the previous year, the business posted $6.27 earnings per share. Humana’s quarterly revenue was up 26.2% on a year-over-year basis. Sell-side analysts expect that Humana Inc. will post 9.09 earnings per share for the current year.

Wall Street Analyst Weigh In

HUM has been the subject of several research analyst reports. Lake Street Capital started coverage on shares of Humana in a report on Thursday, July 30th. They issued a “buy” rating for the company. Robert W. Baird set a $390.00 price target on shares of Humana in a research report on Thursday, July 30th. Barclays upped their price objective on shares of Humana from $344.00 to $407.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. UBS Group started coverage on Humana in a report on Thursday, July 30th. They set a “buy” rating on the stock. Finally, Cantor Fitzgerald lifted their target price on Humana from $264.00 to $300.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 7th. Fourteen research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus price target of $395.22.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.